455 related articles for article (PubMed ID: 32766800)
1. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
2. Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Hu X; Liu Y; He Y; Wang Z; Zhang H; Yang W; Lu J
J Oncol; 2022; 2022():3601942. PubMed ID: 35646119
[TBL] [Abstract][Full Text] [Related]
3. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.
Kawada T; Yanagisawa T; Mostafaei H; Sari Motlagh R; Quhal F; Rajwa P; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pallauf M; Pradere B; Teoh JY; Karakiewicz PI; Araki M; Shariat SF
Eur Urol Focus; 2023 Mar; 9(2):264-274. PubMed ID: 36774273
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status: A Systematic Review and Meta-Analysis of Overall Survival Data.
Butaney M; Satkunasivam R; Goldberg H; Freedland SJ; Patel SP; Hamid O; Pal SK; Klaassen Z; Wallis CJD
Am J Clin Oncol; 2020 Mar; 43(3):193-202. PubMed ID: 31809328
[TBL] [Abstract][Full Text] [Related]
5. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
6. The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Han CL; Tian BW; Yan LJ; Ding ZN; Liu H; Pan GQ; Zhang X; Mao XC; Tan SY; Li RZ; Wang DX; Dong ZR; Yan YC; Li T
Expert Rev Anticancer Ther; 2024 May; 24(5):303-312. PubMed ID: 38623811
[TBL] [Abstract][Full Text] [Related]
7. Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.
Zhao B; Zhao H; Zhao J
Int J Cancer; 2019 Jan; 144(1):169-177. PubMed ID: 30121946
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis.
Yang F; Wang Y; Tang L; Mansfield AS; Adjei AA; Leventakos K; Duma N; Wei J; Wang L; Liu B; Molina JR
Front Oncol; 2022; 12():955440. PubMed ID: 36052255
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis.
Assayag J; Kim C; Chu H; Webster J
Front Oncol; 2023; 13():1194718. PubMed ID: 38162494
[TBL] [Abstract][Full Text] [Related]
13. Patient performance status and cancer immunotherapy efficacy: a meta-analysis.
Bersanelli M; Brighenti M; Buti S; Barni S; Petrelli F
Med Oncol; 2018 Aug; 35(10):132. PubMed ID: 30128793
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
15. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
Dall'Olio FG; Maggio I; Massucci M; Mollica V; Fragomeno B; Ardizzoni A
Lung Cancer; 2020 Jul; 145():95-104. PubMed ID: 32417680
[TBL] [Abstract][Full Text] [Related]
16. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Khaki AR; Li A; Diamantopoulos LN; Bilen MA; Santos V; Esther J; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Assi H; Gartrell BA; Sankin A; Rodriguez-Vida A; Lythgoe M; Pinato DJ; Drakaki A; Joshi M; Isaacsson Velho P; Hahn N; Liu S; Alonso Buznego L; Duran I; Moses M; Jain J; Murgic J; Baratam P; Barata P; Tripathi A; Zakharia Y; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
Cancer; 2020 Mar; 126(6):1208-1216. PubMed ID: 31829450
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
18. Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.
Wallis CJD; Butaney M; Satkunasivam R; Freedland SJ; Patel SP; Hamid O; Pal SK; Klaassen Z
JAMA Oncol; 2019 Apr; 5(4):529-536. PubMed ID: 30605213
[TBL] [Abstract][Full Text] [Related]
19. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study.
Mollica V; Rizzo A; Marchetti A; Tateo V; Tassinari E; Rosellini M; Massafra R; Santoni M; Massari F
Clin Exp Med; 2023 Dec; 23(8):5039-5049. PubMed ID: 37535194
[TBL] [Abstract][Full Text] [Related]
20. Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials.
Parmar K; Subramanyam S; Attwood K; Appiah D; Fountzilas C; Mukherjee S
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
